Methods of using rho kinase inhibitors to treat frontotemporal dementia

Abstract

The present invention relates to methods of treating frontotemporal dementia. The methods are preferably accomplished by treatment with a rho kinase inhibitor, such as fasudil or hydroxyfasudil. In particular, the invention contemplates treatment of the behavioral variant frontotemporal dementia and usually treatment begins once symptoms become evident. Usually, patients treated according to the invention have no neuromuscular symptoms and generally have not been diagnosed with amyotrophic lateral sclerosis, corticobasal degeneration, Parkinson's Disease or progressive supranuclear palsy. A preferred method of the invention involves oral treatment with fasudil, administered in a total daily dose of between 70 mg and 140 mg.

Dependencies are inferred from the claim text.